Your browser doesn't support javascript.
loading
Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes.
Moore, Amy; Machiela, Mitchell J; Machado, Moara; Wang, Sophia S; Kane, Eleanor; Slager, Susan L; Zhou, Weiyin; Carrington, Mary; Lan, Qing; Milne, Roger L; Birmann, Brenda M; Adami, Hans-Olov; Albanes, Demetrius; Arslan, Alan A; Becker, Nikolaus; Benavente, Yolanda; Bisanzi, Simonetta; Boffetta, Paolo; Bracci, Paige M; Brennan, Paul; Brooks-Wilson, Angela R; Canzian, Federico; Caporaso, Neil; Clavel, Jacqueline; Cocco, Pierluigi; Conde, Lucia; Cox, David G; Cozen, Wendy; Curtin, Karen; De Vivo, Immaculata; de Sanjose, Silvia; Foretova, Lenka; Gapstur, Susan M; Ghesquières, Hervè; Giles, Graham G; Glenn, Martha; Glimelius, Bengt; Gao, Chi; Habermann, Thomas M; Hjalgrim, Henrik; Jackson, Rebecca D; Liebow, Mark; Link, Brian K; Maynadie, Marc; McKay, James; Melbye, Mads; Miligi, Lucia; Molina, Thierry J; Monnereau, Alain; Nieters, Alexandra.
Afiliação
  • Moore A; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
  • Machiela MJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
  • Machado M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
  • Wang SS; Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.
  • Kane E; Division of Health Analytics, City of Hope Beckman Research Institute, Duarte, CA 91010, USA.
  • Slager SL; Department of Health Sciences, University of York, York YO10 5DD, UK.
  • Zhou W; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
  • Carrington M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
  • Lan Q; Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD 20877, USA.
  • Milne RL; Basic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, MD 20892, USA.
  • Birmann BM; Ragon Institute of MGH, Cambridge, MA 02139, USA.
  • Adami HO; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
  • Albanes D; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria 3004, Australia.
  • Arslan AA; Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Victoria 3010, Australia.
  • Becker N; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria 3800, Australia.
  • Benavente Y; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Bisanzi S; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17176, Sweden.
  • Boffetta P; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • Bracci PM; Institute of Health and Society, Clinical Effectiveness Research Group, University of Oslo, Oslo 0315, Norway.
  • Brennan P; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
  • Brooks-Wilson AR; Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY 10016, USA.
  • Canzian F; Department of Population Health, New York University School of Medicine, New York, NY 10016, USA.
  • Caporaso N; Perlmutter Comprehensive Cancer Center, NYU Langone Health, New York, NY 10016, USA.
  • Clavel J; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg 69120, Germany.
  • Cocco P; Cancer Epidemiology Research Programme, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
  • Conde L; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Barcelona 08036, Spain.
  • Cox DG; Regional Cancer Prevention Laboratory, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence 50139, Italy.
  • Cozen W; Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA.
  • Curtin K; Department of Medical and Surgical Sciences, University of Bologna, Bologna 41026, Italy.
  • De Vivo I; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94118, USA.
  • de Sanjose S; International Agency for Research on Cancer (IARC), Lyon 69372, France.
  • Foretova L; Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z1L3, Canada.
  • Gapstur SM; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia V5A1S6, Canada.
  • Ghesquières H; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
  • Giles GG; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
  • Glenn M; Center of Research in Epidemiology and Statistics Sorbonne Paris Cité (CRESS), UMR1153, INSERM, Villejuif 75004, France.
  • Glimelius B; Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Monserrato, Cagliari 09042, Italy.
  • Gao C; Bill Lyons Informatics Centre, UCL Cancer Institute, University College London, London WC1E 6DD, UK.
  • Habermann TM; INSERM U1052, Cancer Research Center of Lyon, Centre Léon Bérard, Lyon 69008, France.
  • Hjalgrim H; Department of Preventive Medicine, USC Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
  • Jackson RD; Norris Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
  • Liebow M; Department of Internal Medicine and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
  • Link BK; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • Maynadie M; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
  • McKay J; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
  • Melbye M; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Barcelona 08036, Spain.
  • Miligi L; Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno 656 53, Czech Republic.
  • Molina TJ; Department of Population Science, American Cancer Society, Atlanta, GA 30303, USA.
  • Monnereau A; Department of Hematology, Centre Léon Bérard, Lyon 69008, France.
  • Nieters A; INSERM U1052, Cancer Research Center of Lyon, Lyon-1 University, Pierre-Bénite Cedex 69008, France.
J Transl Genet Genom ; 5: 200-217, 2021.
Article em En | MEDLINE | ID: mdl-34622145
AIM: Recessive genetic variation is thought to play a role in non-Hodgkin lymphoma (NHL) etiology. Runs of homozygosity (ROH), defined based on long, continuous segments of homozygous SNPs, can be used to estimate both measured and unmeasured recessive genetic variation. We sought to examine genome-wide homozygosity and NHL risk. METHODS: We used data from eight genome-wide association studies of four common NHL subtypes: 3061 chronic lymphocytic leukemia (CLL), 3814 diffuse large B-cell lymphoma (DLBCL), 2784 follicular lymphoma (FL), and 808 marginal zone lymphoma (MZL) cases, as well as 9374 controls. We examined the effect of homozygous variation on risk by: (1) estimating the fraction of the autosome containing runs of homozygosity (FROH); (2) calculating an inbreeding coefficient derived from the correlation among uniting gametes (F3); and (3) examining specific autosomal regions containing ROH. For each, we calculated beta coefficients and standard errors using logistic regression and combined estimates across studies using random-effects meta-analysis. RESULTS: We discovered positive associations between FROH and CLL (ß = 21.1, SE = 4.41, P = 1.6 × 10-6) and FL (ß = 11.4, SE = 5.82, P = 0.02) but not DLBCL (P = 1.0) or MZL (P = 0.91). For F3, we observed an association with CLL (ß = 27.5, SE = 6.51, P = 2.4 × 10-5). We did not find evidence of associations with specific ROH, suggesting that the associations observed with FROH and F3 for CLL and FL risk were not driven by a single region of homozygosity. CONCLUSION: Our findings support the role of recessive genetic variation in the etiology of CLL and FL; additional research is needed to identify the specific loci associated with NHL risk.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Transl Genet Genom Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Transl Genet Genom Ano de publicação: 2021 Tipo de documento: Article